ESG

With $11.8M in fresh capital, Axiom Trust is emerging from stealth to modernize the archaic trust administration industry ahead of a massive wealth shift.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

Biosolutions leader Novonesis ranks 6th on the prestigious list, a recognition driven by employee feedback and its deep roots in the state's biotech economy.

As private equity giant EIG sells its entire stake, Diversified Energy counters by repurchasing nearly half the shares in a bold vote of confidence.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

As Cal-Maine preps its Q3 report, investors watch if its pivot to prepared foods and specialty eggs can offset plunging prices and new avian flu threats.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

BETA Technologies will launch electric air services across 10 states, deploying its ALIA aircraft for cargo, medical, and critical logistics missions.

A new report lauds PA's PHARE housing fund for its success, but reveals a staggering 2.5x gap between funding requests and available resources.

Séché Environnement's 2025 results reveal a dual strategy: aggressive international expansion and acquisitions funded by green bonds counter domestic slowdowns.

Ottawa injects over $900M into defence innovation, fueling a new strategy to boost domestic tech, meet NATO commitments, and create high-skill jobs.

A startup using trained dogs and AI to sniff out cancer from breath samples was just named a "Fierce 15" company. Can this technology change screening?

With 8x sales growth and 90% prediction accuracy, AI pioneer QuantHealth is proving that simulating clinical trials can slash pharma's $50B failure rate.

A new partnership is testing if 'brain training' games can boost student performance. But in a field full of hype, can this study deliver real answers?

NOAA's approval of a key application for seabed mining boosts US critical mineral hopes but sparks fierce opposition from scientists and nations fearing ruin.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

A $5M US government investment in a Macedonian antimony mine aims to secure Western supply chains, de-risking a potential IPO for Australia's Pela Global.

With a new chairman at the helm, NATSO's 2026 board is set to navigate the complex challenges of EV charging, new regulations, and evolving customer demands.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.